IN2014DN08325A - - Google Patents

Info

Publication number
IN2014DN08325A
IN2014DN08325A IN8325DEN2014A IN2014DN08325A IN 2014DN08325 A IN2014DN08325 A IN 2014DN08325A IN 8325DEN2014 A IN8325DEN2014 A IN 8325DEN2014A IN 2014DN08325 A IN2014DN08325 A IN 2014DN08325A
Authority
IN
India
Prior art keywords
amino acid
antigens
sequence
difficile toxin
residues
Prior art date
Application number
Inventor
Clifford Shone
April Roberts
SMITH Michael MAYNARD
Original Assignee
Sec Dep For Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sec Dep For Health filed Critical Sec Dep For Health
Publication of IN2014DN08325A publication Critical patent/IN2014DN08325A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

The present invention relates to recombinant Clostridium difficile antigens based on a polypeptide consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500 700 of a C. difficile Toxin A sequence or a C. difficile Toxin B sequence; though with the proviso that the polypeptide does not include one or more Repeat Unit (RU) located between amino acid residues 1851 2710 of C. difficile Toxin A and/ or residues 1853 2366 of a C. difficile Toxin B protein that consists of or comprises a first amino acid sequence and a second amino acid. Also provided is the use of said antigens for the prevention/ treatment/ suppression of Clostridium difficile infection (CDI) together with methods for generating said antigens methods for generating antibodies that bind to said antigens and the use of said antibodies for the prevention/ treatment/ suppression of CDI.
IN8325DEN2014 2012-04-04 2013-04-04 IN2014DN08325A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1206070.3A GB201206070D0 (en) 2012-04-04 2012-04-04 Clostridium difficile antigens
PCT/GB2013/050886 WO2013150309A1 (en) 2012-04-04 2013-04-04 Clostridium difficile antigens

Publications (1)

Publication Number Publication Date
IN2014DN08325A true IN2014DN08325A (en) 2015-05-15

Family

ID=46160352

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8325DEN2014 IN2014DN08325A (en) 2012-04-04 2013-04-04

Country Status (12)

Country Link
US (2) US9315555B2 (en)
EP (1) EP2844283B1 (en)
JP (1) JP2015516964A (en)
CN (1) CN104755099A (en)
AU (1) AU2013245412A1 (en)
BR (1) BR112014024751A2 (en)
CA (1) CA2869109A1 (en)
GB (1) GB201206070D0 (en)
HK (1) HK1202805A1 (en)
IN (1) IN2014DN08325A (en)
SG (1) SG11201406301TA (en)
WO (1) WO2013150309A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2753352T (en) 2010-09-03 2017-05-25 Valneva Austria Gmbh Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
US9730994B2 (en) 2013-06-14 2017-08-15 Sanofi Pasteur, Inc. Compositions and methods for immunizing against C. difficile
US20180110849A1 (en) * 2015-05-15 2018-04-26 Sanofi Pasteur, Inc. Methods for immunizing against clostridium difficile
US10913786B2 (en) 2016-03-21 2021-02-09 Children's Medical Center Corporation Compositions and methods for inhibiting Wnt signaling
CN112512556A (en) * 2018-01-16 2021-03-16 儿童医学中心公司 Compositions and methods for inhibiting WNT signaling
CN113329766A (en) * 2018-11-16 2021-08-31 马特里瓦克斯公司 Clostridium difficile multicomponent vaccine
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
BR112021023119A2 (en) * 2019-05-21 2022-01-25 Univ California Vaccine compositions for clostridium difficile
CN113717263B (en) * 2021-08-04 2022-06-07 河北医科大学第二医院 Clostridium difficile specific antigen peptide
WO2023143559A1 (en) * 2022-01-30 2023-08-03 Westlake University Tfpi binding polypeptides and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
EP2502998A3 (en) * 1999-04-09 2013-02-27 Intercell USA, Inc. Recombinant toxin A/ToxinB vaccine against clostridium difficile
EP1292686A1 (en) 2000-06-07 2003-03-19 Smittskyddsinstitutet Gene expression cassette and its use
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
WO2006121422A2 (en) 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
CA2659684A1 (en) 2006-08-02 2008-02-07 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
US8986697B2 (en) 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens

Also Published As

Publication number Publication date
WO2013150309A8 (en) 2014-12-24
JP2015516964A (en) 2015-06-18
WO2013150309A9 (en) 2015-04-09
CA2869109A1 (en) 2013-10-10
SG11201406301TA (en) 2014-11-27
AU2013245412A1 (en) 2014-10-16
US9896514B2 (en) 2018-02-20
CN104755099A (en) 2015-07-01
US20160319037A1 (en) 2016-11-03
GB201206070D0 (en) 2012-05-16
US9315555B2 (en) 2016-04-19
HK1202805A1 (en) 2015-10-09
EP2844283A1 (en) 2015-03-11
US20150093389A1 (en) 2015-04-02
BR112014024751A2 (en) 2017-07-11
EP2844283B1 (en) 2019-06-12
WO2013150309A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
IN2014DN08325A (en)
WO2012046061A3 (en) Clostridium difficile antigens
MX2020003260A (en) Fc-receptor binding modified asymmetric antibodies and methods of use.
MX2021006017A (en) Methods and compositions for treatment of disorders with follistatin polypeptides.
IN2014KN01715A (en)
MX2016007429A (en) A peptide mixture.
NZ705370A (en) Fcγriib-specific fc region variant
CY1119916T1 (en) IMMUNE COMPOSITION
ZA202200648B (en) Immunoglobulins and uses thereof
IN2014DN10288A (en)
ES2722773T3 (en) Modified Meningococcal fHbp Polypeptides
MX2016004579A (en) Tm4sf1 binding proteins and methods of using same.
EA201390820A1 (en) Fusion protein against cancer
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
EA201491277A1 (en) ANTI-TRACT FUSE PROTEIN
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2017005467A (en) Serpin fusion polypeptides and methods of use thereof.
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
EP2552462A4 (en) Ccn3 peptides and analogs thereof for therapeutic use
MX365560B (en) Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses.
MX2015002279A (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.
MX2019006446A (en) Methods of inducing immune tolerance to clotting factors.
MX2018014716A (en) Anti-tnfrsf25 antibodies.
NZ700199A (en) Epsilon toxin epitopes from clostridium perfringens with reduced toxicity
WO2018066948A3 (en) Recombinant antigen protein composed of multiple epitopes and method for producing same